Andrew Campbell

Andrew Campbell

Auto-generated profile, based on publicly available information

Andrew Campbell

Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, Cambridge CB21 6GH, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AAAkosua B. Anane-Adjei
Akosua B. Anane-Adjei
EJEsther Jacobs
Esther Jacobs
SNSamuel C. Nash
Samuel C. Nash
SASean Askin
Sean Askin
RSRamesh Soundararajan
Ramesh Soundararajan
ACAndrew Campbell
Andrew Campbell

13 July 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
BBBernard Barlaam
Bernard Barlaam
ECElaine Cadogan
Elaine Cadogan
ACAndrew Campbell
Andrew Campbell
NCNicola Colclough
Nicola Colclough
ADAllan Dishington
Allan Dishington
BZBaochang Zhai
Baochang Zhai
We report the discovery of a novel series of 3-cinnoline carboxamides as highly potent and selective ATM inhibitors. Optimisation of this series focusing on potency and physicochemical properties (especially permeability) led to the identification of compound 21, a highly potent ATM inhibitor (ATM cell IC50 0.0028 μM) with excellent kinase selectivity and favourable physicochemical and pharmacokinetics properties. In vivo, 21 in combination with irinotecan showed tumour regression in the SW620 colorectal tumour xenograft model, superior inhibition to irinotecan alone. Compound 21 was selected for pre-clinical evaluation alongside AZD0156.